Upcoming Webinar: Accelerating Digital Drug Design With Automated Informatics Workflow
In partnership with
Accelerating Digital Drug Design With Automated Informatics Workflow
September 8, 2022 • 8:00AM (PT), 11:00AM (ET), 16:00 (BST)
Modern drug discovery has become increasingly data-driven. Physics, machine learning, and omics-based approaches have all contributed to an explosion in data complexity which can pose significant challenges to scientists and project teams.
In this webinar, research leaders from Maze Therapeutics and Indiana Biosciences Research Institute (IBRI) will discuss their best practices in managing and deriving insights from complex data by leveraging best-in-class informatics tools to create discovery workflows that span data capture and organization to compound design and analysis.
Featuring these leading scientists...
Jay McGill, PhD
Chief Operating Officer,
Jay McGill has more than 25 years of experience in pharmaceutical research and development, research collaborations, and outsourcing management.
Prior to joining IBRI, he served as Senior Director at Eli Lilly and Company in Lilly Research Laboratories responsible for science and technology partnerships. In this role, he served as the interface between academic institutions and Lilly Research Labs as well as overseeing Lilly's portfolio of research-based public/private partnerships and consortium participation.
Mary Mader, PhD
VP Molecular Innovation,
Mary Mader joined IBRI with more than 20 years of experience as a drug hunter in the pharmaceutical and biotech sectors. She is passionate about exploring the intersection of lab-based chemistry and computer-based approaches for identifying and improving potential new drugs.
At Eli Lilly and Relay Therapeutics, she addressed problems across the cycle of drug discovery from project initiation to delivery of new drugs into clinical testing, and she has been associated with seven novel compounds for clinical development.
VP Research Infrastructure,
Vipin Vijayakumar joined Maze Therapeutics in 2018 and has been instrumental in developing and scaling the company's research infrastructure. Maze Therapeutics has an ongoing Phase 1 clinical trial for an oral treatment for Pompe disease.
Previously, he held leadership positions at Cytokinetics where he drove technology solutions supporting Drug Discovery and Clinical Development, and managed engineering, automation, sample management, informatics and software development functions.